Physician profile
Emily S Cline
NPI 1770208217
$7,617.95
in general payments reported to CMS, 2019-2025
33 companies · $2,817 in 2025
The $2,817 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $276 · 2023: $2,040 · 2024: $2,485 · 2025: $2,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,342.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,592.96 | 2023-2025 | |
| Novo Nordisk INC | $1,454.35 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,133.42 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $688.55 | 2022-2025 | Repatha, Evenity, Repatha |
| Lilly USA, LLC | $489.24 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $309.91 | 2024-2025 | Voquezna |
| Pfizer INC. | $222.08 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $180.40 | 2022-2025 | |
| Phadia US INC. | $169.56 | 2023-2024 | Immunocap |
| Axsome Therapeutics, INC. | $159.37 | 2025 | Auvelity |
| Exact Sciences Corporation | $149.03 | 2024-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $96.40 | 2024-2025 | Eliquis |
| Astellas Pharma US INC | $92.03 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.55 | 2023-2025 | Xifaxan |
| Corcept Therapeutics | $88.29 | 2025 | Korlym |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $81.46 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $67.25 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $61.02 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.80 | 2023-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $54.16 | 2023-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Dynavax Technologies Corporation | $50.44 | 2023-2024 | Heplisav-B |
| Glaxosmithkline, LLC. | $49.90 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Ardelyx, INC. | $41.18 | 2025 | Ibsrela |
| Organon LLC | $34.50 | 2023 | Renflexis, Hadlima |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.73 | 2023 | |
| Kyowa Kirin, INC. | $32.78 | 2025 | |
| Daiichi Sankyo INC. | $23.95 | 2024 | Injectafer |
| Ucb, INC. | $22.81 | 2025 | Bimzelx |
| Teva Pharmaceuticals USA, INC. | $19.66 | 2023 | |
| Genzyme Corporation | $19.24 | 2023 | |
| Sandoz INC. | $18.83 | 2023 | Hyrimoz |
| Janssen Pharmaceuticals, INC | $15.90 | 2023 | Xarelto |
| Currax Pharmaceuticals LLC | $15.20 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.